Rachel Riechelmann: Systemic review on TKI efficacy and safety in patients with neuroendocrine tumors

Rachel Riechelmann, Professor at AC Camargo Cancer Center, shared on X:

“Our systemic review on TKI efficacy and safety in patients with neuroendocrine tumors.”

Rachel Riechelmann is the Director of the Clinical Oncology Department and Professor at AC Camargo Cancer Center, Sao Paulo, Brazil and also serves as the President of the Brazilian GI Tumors Group (GTG).

She has more than 125 publications in peer-reviewed journals and is editor of the book Methods and Biostatistics in Oncology: Understanding Clinical Research as an Applied Tool, Springer 2018.

Prof. Riechelmann is a member of ESMO Scientific Committees (Colorectal and NET), Latin American Society of GI Oncology (SLAGO), the European Society of Neuroendocrine Tumors Advisory Board and Chair – GI LACOG (Latin American Cooperative Oncology Group).